{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:33:40Z","timestamp":1793277220775,"version":"4.5.0"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11095-025-03857-9","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:58:02Z","timestamp":1745423882000},"page":"547-578","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Nitrosamine Drug Substance-Related Impurities (NDSRIs) in Pharmaceuticals: Formation, Mitigation Strategies, and Emphasis on Mutagenicity Risks"],"prefix":"10.1007","volume":"42","author":[{"given":"Dande","family":"Aishwarya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi","family":"Ramakant Dhampalwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Pallaprolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1932-637X","authenticated-orcid":false,"given":"Ramalingam","family":"Peraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"3857_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jsps.2022.12.010","volume":"31","author":"W Wichitnithad","year":"2023","unstructured":"Wichitnithad W, Nantaphol S, Noppakhunsomboon K, Rojsitthisak P. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals. Saudi Pharmaceutical Journal. 2023;31:295\u2013311.","journal-title":"Saudi Pharmaceutical Journal"},{"key":"3857_CR2","doi-asserted-by":"publisher","first-page":"105355","DOI":"10.1016\/j.yrtph.2023.105355","volume":"139","author":"H Akkaraju","year":"2023","unstructured":"Akkaraju H, Tatia R, Mane SS, Khade AB, Dengale SJ. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products. Regul Toxicol Pharmacol. 2023;139:105355.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3857_CR3","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1016\/j.xphs.2021.04.021","volume":"110","author":"B Tuesuwan","year":"2021","unstructured":"Tuesuwan B, Vongsutilers V. Nitrosamine contamination in pharmaceuticals: threat, impact, and control. J Pharm Sci. 2021;110:3118\u201328.","journal-title":"J Pharm Sci"},{"key":"3857_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/0165-1218(91)90123-4","volume":"259","author":"AR Tricker","year":"1991","unstructured":"Tricker AR, Preussmann R. Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential. Mutation Research\/Genetic Toxicology. 1991;259:277\u201389.","journal-title":"Mutation Research\/Genetic Toxicology"},{"key":"3857_CR5","unstructured":"US FDA. Control of nitrosamine impurities in human drugs, guidance for industry. U.S. department of health and human services, food and drug administration, Center for Drug Evaluation and Research (CDER), pharmaceutical quality\/manufacturing standards (CGMP). 2024. Available from: https:\/\/www.fda.gov\/media\/141720\/download. Accessed 11 Oct 2024."},{"key":"3857_CR6","unstructured":"Agency for toxic substances and disease registry. Toxicological profile for N-nitrosodimethylamine (NDMA). 2023. Available from: https:\/\/www.atsdr.cdc.gov\/toxprofiles\/tp141.pdf. Accessed 14 Oct 2024."},{"key":"3857_CR7","unstructured":"US FDA. FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity. 2018. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-announces-voluntary-recall-several-medicines-containing-valsartan-following-detection-impurity. Accessed 11 Oct 2024."},{"key":"3857_CR8","unstructured":"EMA. EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity: some valsartan medicines being recalled across the EU. 2018. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-reviewing-medicines-containing-valsartan-zhejiang-huahai-following-detection-impurity-some-valsartan-medicines-being-recalled-across-eu. Accessed 11 Oct 2024."},{"key":"3857_CR9","unstructured":"US FDA. FDA Updates and Press Announcements on NDMA in Zantac (ranitidine). 2020."},{"key":"3857_CR10","unstructured":"US FDA. FDA requests removal of all ranitidine products (Zantac) from the Market. 2020. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-requests-removal-all-ranitidine-products-zantac-market. Accessed 11 Oct 2024."},{"key":"3857_CR11","unstructured":"US FDA. FDA updates and press announcements on NDMA in metformin. 2020. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-ndma-metformin#:~:text=Update%20%5B10%2F5%2F2020,above%20the%20acceptable%20intake%20limit. Accessed 11 Oct 2024."},{"key":"3857_CR12","unstructured":"US FDA. Statement from Janet Woodcock, M.D., director of FDA\u2019s center for drug evaluation and research, on impurities found in diabetes drugs outside the U.S. 2019. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/statement-janet-woodcock-md-director-fdas-center-drug-evaluation-and-research-impurities-found. Accessed 18 Oct 2024."},{"key":"3857_CR13","unstructured":"US FDA. FDA updates and press announcements on nitrosamines in rifampin and rifapentine. 2020. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-nitrosamines-rifampin-and-rifapentine. Accessed 11 Oct 2024."},{"key":"3857_CR14","unstructured":"EMA. Nitrosamine impurities in human medicinal products. 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/opinion-any-scientific-matter\/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf. Accessed 11 Oct 2024."},{"key":"3857_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1021\/acs.chemrestox.3c00327","volume":"37","author":"DJ Snodin","year":"2024","unstructured":"Snodin DJ, Trejo-Martin A, Ponting DJ, Smith GF, Czich A, Cross K, et al. Mechanisms of Nitrosamine Mutagenicity and Their Relationship to Rodent Carcinogenic Potency. Chem Res Toxicol. 2024;37:181\u201398.","journal-title":"Chem Res Toxicol"},{"key":"3857_CR16","unstructured":"US FDA. Updates on possible mitigation strategies to reduce the risk of nitrosamine drug substance-related impurities in drug products. US Food and Drug Administration. 2021. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/updates-possible-mitigation-strategies-reduce-risk-nitrosamine-drug-substance-related-impurities. Accessed 11 Oct 2024."},{"key":"3857_CR17","doi-asserted-by":"crossref","unstructured":"Hu J, Christison T, Rohrer J. Determination of dimethylamine and nitrite in pharmaceuticals by ion chromatography to assess the likelihood of nitrosamine formation. Heliyon. 2021;7.","DOI":"10.1016\/j.heliyon.2021.e06179"},{"key":"3857_CR18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.foodchem.2014.11.101","volume":"174","author":"SS Herrmann","year":"2015","unstructured":"Herrmann SS, Granby K, Duedahl-Olesen L. Formation and mitigation of N-nitrosamines in nitrite preserved cooked sausages. Food Chem. 2015;174:516\u201326.","journal-title":"Food Chem"},{"key":"3857_CR19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.xphs.2023.01.027","volume":"112","author":"J Moser","year":"2023","unstructured":"Moser J, Ashworth IW, Harris L, Hillier MC, Nanda KK, Scrivens G. N-nitrosamine formation in pharmaceutical solid drug products: experimental observations. J Pharm Sci. 2023;112:1255\u201367.","journal-title":"J Pharm Sci"},{"key":"3857_CR20","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.xphs.2022.11.013","volume":"112","author":"J Schlingemann","year":"2023","unstructured":"Schlingemann J, Burns MJ, Ponting DJ, Avila CM, Romero NE, Jaywant MA, et al. The landscape of potential small and drug substance related nitrosamines in pharmaceuticals. J Pharm Sci. 2023;112:1287\u2013304.","journal-title":"J Pharm Sci"},{"key":"3857_CR21","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.xphs.2022.12.022","volume":"112","author":"S Horne","year":"2023","unstructured":"Horne S, Vera MD, Nagavelli LR, Sayeed VA, Heckman L, Johnson D, et al. Regulatory experiences with root causes and risk factors for nitrosamine impurities in pharmaceuticals. J Pharm Sci. 2023;112:1166\u201382.","journal-title":"J Pharm Sci"},{"key":"3857_CR22","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.3390\/pr10112428","volume":"10","author":"M Hom\u0161ak","year":"2022","unstructured":"Hom\u0161ak M, Trampu\u017e M, Naver\u0161nik K, Kitanovski Z, \u017dnidari\u010d M, Kiefer M, et al. Assessment of a Diverse Array of Nitrite Scavengers in Solution and Solid State: A Study of Inhibitory Effect on the Formation of Alkyl-Aryl and Dialkyl N-Nitrosamine Derivatives. Processes. 2022;10:2428.","journal-title":"Processes"},{"key":"3857_CR23","unstructured":"US FDA. Recommended acceptable intake limits for nitrosamine drug substancerelated impurities (NDSRIs) guidance for industry. 2023. Available from: https:\/\/www.fda.gov\/media\/170794\/download. Accessed 3 Oct 2024."},{"key":"3857_CR24","unstructured":"Purchase IFH. A comparison of the potency of the mutagenic effect of chemicals in short-term tests with their carcinogenic effect in rodent carcinogenicity experiments. Methods for estimating risk ofchemical injury: human and non-human biota and ecosystems New York: John Wiley; 1985. p. 247\u201369."},{"key":"3857_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0165-1218(88)90017-1","volume":"205","author":"J McCann","year":"1988","unstructured":"McCann J, Swirsky Gold L, Horn L, McGill R, Graedel TE, Kaldor J. Statistical analysis of Salmonella test data and comparison to results of animal cancer tests. Mutation Research\/Genetic Toxicology. 1988;205:183\u201395.","journal-title":"Mutation Research\/Genetic Toxicology"},{"key":"3857_CR26","unstructured":"US FDA. Control of Nitrosamine Impurities in Human Drugs. 2021 Feb."},{"key":"3857_CR27","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1007\/s00508-021-01822-1","volume":"133","author":"B Sadasivam","year":"2021","unstructured":"Sadasivam B, Fatima Z, Atal S. Metformin recalls: regulatory background, concerns and challenges. Wien Klin Wochenschr. 2021;133:851\u20134.","journal-title":"Wien Klin Wochenschr"},{"key":"3857_CR28","unstructured":"US FDA. FDA updates and press announcements on angiotensin II receptor blocker (ARB) recalls (Valsartan, Losartan, and Irbesartan. US Food and Drug Administration. 2019. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan?utm_campaign=FDA%20updates%20on%20angiotensin%20II%20receptor%20blocker%20%28ARB%29%20recalls%3A%20ScieGen%E2%80%99s%20irbesartan%20recalled%20due&utm_medium=email. Accessed 11 Oct 2024."},{"key":"3857_CR29","unstructured":"US FDA. FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall. US Food and Drug Administration. 2019. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-statement-fdas-ongoing-investigation-valsartan-and-arb-class-impurities-and-agencys-steps. Accessed 10 Oct 2024."},{"key":"3857_CR30","unstructured":"US FDA. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) method for the determination of NDMA in metformin drug substance and drug product. US Food and Drug Administration. 2020. Available from: https:\/\/www.fda.gov\/media\/134914\/download. Accessed 14 Oct 2024."},{"key":"3857_CR31","unstructured":"US FDA. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) method for the determination of six nitrosamine impurities in ARB drugs. US Food and Drug Administration. 2019 [cited 2024 Jan 11]. Available from: https:\/\/www.fda.gov\/media\/125478\/download. Accessed 14 Oct 2024."},{"key":"3857_CR32","unstructured":"US FDA. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) method for the determination of ndma in ranitidine drug substance and drug product. US Food and Drug Administration. 2019. Available from: https:\/\/www.fda.gov\/media\/130801\/download#:~:text=This%20method%20will%20be%20used,drug%20substance%20or%20drug%20product.&text=N%2Dnitroso%2Ddi%2Dmethylamine%20(NDMA)%20impurity%20is,accuracy%20(HRAM)%20mass%20spectrometer. Accessed 14 Oct 2024."},{"key":"3857_CR33","unstructured":"US FDA. Liquid chromatography-high resolution mass spectrometry (LC-ESI-HRMS) method for the determination of varenicline nitrosamine drug substance-related impurity (NDSRI) in varenicline drug product and drug substance. 2024. Available from: https:\/\/www.fda.gov\/media\/175552\/download. Accessed 14 Oct 2024."},{"key":"3857_CR34","unstructured":"EMA. Questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/opinion-any-scientific-matter\/nitrosamines-emea-h-a53-1490-questions-answers-marketing-authorisation-holders-applicants-chmp-opinion-article-53-regulation-ec-no-726-2004-referral-nitrosamine-impurities-human-medicinal-products_en.pdf. Accessed 12 Oct 2024."},{"key":"3857_CR35","unstructured":"EMA. Appendix 2 to questions and answers for marketing authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products carcinogenic potency categorisation approach for nnitrosamines. 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-2-carcinogenic-potency-categorisation-approach-n-nitrosamines_en.pdf. Accessed 12 Oct 2024."},{"key":"3857_CR36","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1021\/acs.joc.0c02774","volume":"86","author":"JC Beard","year":"2021","unstructured":"Beard JC, Swager TM. An organic chemist\u2019s guide to N-nitrosamines: their structure, reactivity, and role as contaminants. J Org Chem. 2021;86:2037\u201357.","journal-title":"J Org Chem"},{"key":"3857_CR37","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1021\/acs.oprd.0c00323","volume":"24","author":"R L\u00f3pez-Rodr\u00edguez","year":"2020","unstructured":"L\u00f3pez-Rodr\u00edguez R, McManus JA, Murphy NS, Ott MA, Burns MJ. Pathways for N-nitroso compound formation: secondary amines and beyond. Org Process Res Dev. 2020;24:1558\u201385.","journal-title":"Org Process Res Dev"},{"key":"3857_CR38","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1021\/acs.oprd.4c00088","volume":"28","author":"L Badia","year":"2024","unstructured":"Badia L, Camps H, Lloveras I, Handler N, Buschmann H, Valls J, et al. Strategy to Assess and Control Nitrosamine Formation in API during Storage: A Sitagliptin Case Study. Org Process Res Dev. 2024;28:3182\u201396.","journal-title":"Org Process Res Dev"},{"key":"3857_CR39","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1021\/acs.oprd.3c00153","volume":"27","author":"RC Cioc","year":"2023","unstructured":"Cioc RC, Joyce C, Mayr M, Bream RN. Formation of N-nitrosamine drug substance related impurities in medicines: a regulatory perspective on risk factors and mitigation strategies. Org Process Res Dev. 2023;27:1736\u201350.","journal-title":"Org Process Res Dev"},{"key":"3857_CR40","doi-asserted-by":"publisher","first-page":"13092","DOI":"10.1038\/srep13092","volume":"5","author":"H Miao","year":"2015","unstructured":"Miao H, Chen L, Hao L, Zhang X, Chen Y, Ruan Z, et al. Stearic acid induces proinflammatory cytokine production partly through activation of lactate-HIF1\u03b1 pathway in chondrocytes. Sci Rep. 2015;5:13092.","journal-title":"Sci Rep"},{"key":"3857_CR41","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1021\/acs.oprd.0c00224","volume":"24","author":"IW Ashworth","year":"2020","unstructured":"Ashworth IW, Dirat O, Teasdale A, Whiting M. Potential for the formation of N-nitrosamines during the manufacture of active pharmaceutical ingredients: an assessment of the risk posed by trace nitrite in water. Org Process Res Dev. 2020;24:1629\u201346.","journal-title":"Org Process Res Dev"},{"key":"3857_CR42","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1021\/acs.oprd.0c00462","volume":"24","author":"FJ King","year":"2020","unstructured":"King FJ, Searle AD, Urquhart MW. Ranitidine\u2014Investigations into the Root Cause for the Presence of N -Nitroso- N, N -dimethylamine in Ranitidine Hydrochloride Drug Substances and Associated Drug Products. Org Process Res Dev. 2020;24:2915\u201326.","journal-title":"Org Process Res Dev"},{"key":"3857_CR43","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.xphs.2022.11.011","volume":"112","author":"P Harmon","year":"2023","unstructured":"Harmon P. Ranitidine: A Proposed Mechanistic Rationale for NDMA Formation and a Potential Control Strategy. J Pharm Sci. 2023;112:1220\u20134.","journal-title":"J Pharm Sci"},{"key":"3857_CR44","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1016\/S0040-4039(00)88318-5","volume":"24","author":"RN Loeppky","year":"1983","unstructured":"Loeppky RN, Outram JR, Tomasik W, Faulconer JM. Rapid nitrosamine formation from a tertiary amine: The nitrosation of 2-(N, N-Dimethylaminomethyl)pyrrole. Tetrahedron Lett. 1983;24:4271\u20134.","journal-title":"Tetrahedron Lett"},{"key":"3857_CR45","unstructured":"European Pharmacopeia, Trolamine Monograph, Edition 10.5. Strasbourg; 2021."},{"key":"3857_CR46","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.xphs.2022.04.016","volume":"112","author":"R Boetzel","year":"2023","unstructured":"Boetzel R, Schlingemann J, Hickert S, Korn C, Kocks G, Luck B, et al. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products. J Pharm Sci. 2023;112:1615\u201324.","journal-title":"J Pharm Sci"},{"key":"3857_CR47","doi-asserted-by":"publisher","first-page":"115066","DOI":"10.1016\/j.jpba.2022.115066","volume":"222","author":"G Hao","year":"2023","unstructured":"Hao G, Hu R, Wang X, Gao P, Wang L, Jiang M, et al. N-Nitrosodimethylamine formation in metformin hydrochloride sustained-release tablets: Effects of metformin and hypromellose used in drug product formulation. J Pharm Biomed Anal. 2023;222:115066.","journal-title":"J Pharm Biomed Anal"},{"key":"3857_CR48","unstructured":"Lhasa. Lhasa carcinogenicity database (LCDB). Available from: https:\/\/www.lhasalimited.org\/solutions\/carcinogenicity-assessment\/. Accessed 3 Oct 2024."},{"key":"3857_CR49","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1208\/s12249-011-9677-z","volume":"12","author":"Y Wu","year":"2011","unstructured":"Wu Y, Levons J, Narang AS, Raghavan K, Rao VM. Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility. AAPS PharmSciTech. 2011;12:1248\u201363.","journal-title":"AAPS PharmSciTech"},{"key":"3857_CR50","doi-asserted-by":"crossref","unstructured":"Keeper LK, Roller PP. N-nitrosation by nitrite ion in neutral and basic medium. Science (1979). 1973;181:1245\u20137.","DOI":"10.1126\/science.181.4106.1245"},{"key":"3857_CR51","doi-asserted-by":"crossref","unstructured":"Casado J, Mosquera M, Paz LC, Prieto MFR, Tato JV. Nitrite ion as a nitrosating reagent. Nitrosation of morpholine and diethylamine in the presence of formaldehyde. Journal of the Chemical Society, Perkin Transactions 2. 1984;1963.","DOI":"10.1039\/p29840001963"},{"key":"3857_CR52","unstructured":"Archer MC, Tannenbaum SR, Wishnok JS. Nitrosamine formation in the presence of carbonyl compounds. IARC Sci Publ. 1976;141\u20135."},{"key":"3857_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.chroma.2005.10.084","volume":"1104","author":"Z Li","year":"2006","unstructured":"Li Z, Jacobus LK, Wuelfing WP, Golden M, Martin GP, Reed RA. Detection and quantification of low-molecular-weight aldehydes in pharmaceutical excipients by headspace gas chromatography. J Chromatogr A. 2006;1104:1\u201310.","journal-title":"J Chromatogr A"},{"key":"3857_CR54","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.xphs.2022.10.033","volume":"112","author":"P Harmon","year":"2023","unstructured":"Harmon P. Trace Aldehydes in Solid Oral Dosage Forms as Catalysts for Nitrosating Secondary Amines. J Pharm Sci. 2023;112:1216\u20139.","journal-title":"J Pharm Sci"},{"key":"3857_CR55","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1002\/jps.23198","volume":"101","author":"JN Hemenway","year":"2012","unstructured":"Hemenway JN, Carvalho TC, Rao VM, Wu Y, Levons JK, Narang AS, et al. Formation of Reactive Impurities in Aqueous and Neat Polyethylene Glycol 400 and Effects of Antioxidants and Oxidation Inducers. J Pharm Sci. 2012;101:3305\u201318.","journal-title":"J Pharm Sci"},{"key":"3857_CR56","doi-asserted-by":"publisher","first-page":"114872","DOI":"10.1016\/j.jpba.2022.114872","volume":"218","author":"J Jire\u0161","year":"2022","unstructured":"Jire\u0161 J, Dou\u0161a M, Gibala P, Kubelka T. N-Nitrosation in the absence of nitrosating agents in pharmaceuticals? J Pharm Biomed Anal. 2022;218:114872.","journal-title":"J Pharm Biomed Anal"},{"key":"3857_CR57","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.xphs.2023.03.007","volume":"112","author":"N Golob","year":"2023","unstructured":"Golob N, Peterlin S, Grahek R, Ro\u0161kar R. NDMA Formation Due to Active Ingredient Degradation and Nitrite Traces in Drug Product. J Pharm Sci. 2023;112:1277\u201386.","journal-title":"J Pharm Sci"},{"key":"3857_CR58","doi-asserted-by":"publisher","first-page":"444","DOI":"10.25082\/JPBR.2024.01.001","volume":"6","author":"R Tiwari","year":"2024","unstructured":"Tiwari R, Mahalpure GS, Mahalpure S, Tiwari A. The clinical and regulatory status of NDSRI: A global imperative. Journal of Pharmaceutical and Biopharmaceutical Research. 2024;6:444\u201358.","journal-title":"Journal of Pharmaceutical and Biopharmaceutical Research"},{"key":"3857_CR59","unstructured":"US FDA. Liquid chromatography-electrospray ionization-high resolution mass spectrometry (LC-ESI-HRMS) method for the determination of nitrosamine impurities in metformin drug substance and drug product. US Food and Drug Administration. 2020 [cited 2024 Jan 20]. Available from: https:\/\/www.fda.gov\/media\/138617\/download. Accessed 12 Oct 2024."},{"key":"3857_CR60","unstructured":"US FDA. Liquid chromatography-high resolution mass spectrometry (LC-ESI-HRMS) method for the determination of N-nitroso-bumetanide in bumetanide drug products and drug substance. 2024. Available from: https:\/\/www.fda.gov\/media\/175550\/download?attachment. Accessed 3 Oct 2024."},{"key":"3857_CR61","doi-asserted-by":"publisher","first-page":"101495","DOI":"10.1016\/j.scp.2024.101495","volume":"38","author":"S Nakka","year":"2024","unstructured":"Nakka S, Muchakayala SK, Surya SBM. A novel and eco-friendly UPLC-ESI-MS method for the quantification of Aceclofenac-NDSRI (Nitroso Drug Substance Related Impurity) from Aceclofenac drug substance and combination formulations. Sustain Chem Pharm. 2024;38:101495.","journal-title":"Sustain Chem Pharm"},{"key":"3857_CR62","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.52711\/0974-360X.2024.00270","volume":"17","author":"U Vidyamani","year":"2024","unstructured":"Vidyamani U, Ramachandran D, Babu MD, Raju SSM, Maheswar KU. Development and Validation of a Rapid and Sensitive LC-APCI-MS\/MS Method for the determination of three N-nitrosamine impurities in Varenicline tartrate drug substance and drug products. Res J Pharm Technol. 2024;17:1703\u201310.","journal-title":"Res J Pharm Technol"},{"key":"3857_CR63","doi-asserted-by":"publisher","first-page":"103349","DOI":"10.1016\/j.jksus.2024.103349","volume":"36","author":"A Bhimireddy","year":"2024","unstructured":"Bhimireddy A, Kumar JVS, Chittireddy HNPR, Shaik MR, Assal ME, Khan M. Safety and human health: The landscape of an effective UPLC-MS\/MS method for the identification and quantification of N-Nitroso Hydrochlorothiazide impurity in Hydrochlorothiazide. Journal of King Saud University-Science. 2024;36:103349.","journal-title":"Journal of King Saud University-Science"},{"key":"3857_CR64","doi-asserted-by":"publisher","first-page":"8773","DOI":"10.1021\/acsomega.3c05170","volume":"9","author":"S Nakka","year":"2024","unstructured":"Nakka S, Katari NK, Muchakayala SK, Jonnalagadda SB, Manabolu Surya SB. Synthesis and Trace-Level Quantification of Mutagenic and Cohort-of-Concern Ciprofloxacin Nitroso Drug Substance-Related Impurities (NDSRIs) and Other Nitroso Impurities Using UPLC-ESI-MS\/MS\u2500 Method Optimization Using I-Optimal Mixture Design. ACS Omega. 2024;9:8773\u201388.","journal-title":"ACS Omega"},{"key":"3857_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2024.03.006","volume-title":"Trace level quantification of N-nitrosorasagiline in rasagiline tablets by LC-TQ-MS\/MS","author":"R Patel","year":"2024","unstructured":"Patel R, Patel M, Solanki R, Khunt D. Trace level quantification of N-nitrosorasagiline in rasagiline tablets by LC-TQ-MS\/MS. Ann Pharm Fr: Elsevier; 2024."},{"key":"3857_CR66","unstructured":"US FDA. Liquid chromatography-high resolution mass spectrometry (LC-HRMS) method for the determination of N-nitroso-propranolol in propranolol hydrochloride oral solution. 2024. Available from: https:\/\/www.fda.gov\/media\/175551\/download?attachment. Accessed 3 Oct 2024."},{"key":"3857_CR67","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1021\/acs.oprd.3c00100","volume":"27","author":"R Nudelman","year":"2023","unstructured":"Nudelman R, Kocks G, Mouton B, Ponting DJ, Schlingemann J, Simon S, et al. The nitrosamine \u201csaga\u201d: lessons learned from five years of scrutiny. Org Process Res Dev. 2023;27:1719\u201335.","journal-title":"Org Process Res Dev"},{"key":"3857_CR68","doi-asserted-by":"publisher","first-page":"e9747","DOI":"10.1002\/rcm.9747","volume":"38","author":"D Aishwarya","year":"2024","unstructured":"Aishwarya D, Nikhil P, Natesan S, Velayutham R, Peraman R. Development and validation of high-performance liquid chromatography-Orbitrap mass spectrometric method for quantification of NDMA in ranitidine drug products and evaluation of antioxidants as inhibitors of classical nitrosation reaction. Rapid Commun Mass Spectrom. 2024;38:e9747.","journal-title":"Rapid Commun Mass Spectrom"},{"key":"3857_CR69","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1093\/carcin\/5.3.309","volume":"5","author":"W Kuenzig","year":"1984","unstructured":"Kuenzig W, Chau J, Norkus E, Holowaschenko H, Newmark H, Mergens W, et al. Caffeic and ferulic acid as blockers of nitrosamine formation. Carcinogenesis. 1984;5:309\u201313.","journal-title":"Carcinogenesis"},{"key":"3857_CR70","doi-asserted-by":"crossref","unstructured":"Mergens WJ, Newmark HL. Antioxidants as Blocking Agents Against Nitrosamine Formation. Autoxidation in Food and Biological Systems. Boston, MA: Springer US; 1980. p. 387\u2013403.","DOI":"10.1007\/978-1-4757-9351-2_21"},{"key":"3857_CR71","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1016\/j.xphs.2021.08.010","volume":"110","author":"KK Nanda","year":"2021","unstructured":"Nanda KK, Tignor S, Clancy J, Marota MJ, Allain LR, D\u2019Addio SM. Inhibition of N-Nitrosamine Formation in Drug Products: A Model Study. J Pharm Sci. 2021;110:3773\u20135.","journal-title":"J Pharm Sci"},{"key":"3857_CR72","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1016\/j.xphs.2023.03.022","volume":"112","author":"A-CV Bayne","year":"2023","unstructured":"Bayne A-CV, Misic Z, Stemmler RT, Wittner M, Frerichs M, Bird JK, et al. N-nitrosamine mitigation with nitrite scavengers in oral pharmaceutical drug products. J Pharm Sci. 2023;112:1794\u2013800.","journal-title":"J Pharm Sci"},{"issue":"177","key":"3857_CR73","first-page":"65","volume":"1972","author":"SS Mirvish","year":"1979","unstructured":"Mirvish SS, Wallcave L, Eagen M, Shubik P. Ascorbate-nitrite reaction: possible means of blocking the formation of carcinogenic N-nitroso compounds. Science. 1979;1972(177):65\u20138.","journal-title":"Science"},{"key":"3857_CR74","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1021\/jf000147+","volume":"48","author":"T Rundl\u00f6f","year":"2000","unstructured":"Rundl\u00f6f T, Olsson E, Wiernik A, Back S, Aune M, Johansson L, et al. Potential nitrite scavengers as inhibitors of the formation of N-nitrosamines in solution and tobacco matrix systems. J Agric Food Chem. 2000;48:4381\u20138.","journal-title":"J Agric Food Chem"},{"key":"3857_CR75","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/BF02855742","volume":"12","author":"JS Choi","year":"1989","unstructured":"Choi JS, Park SH, Choi J-H. Nitrite scavenging effect by flavonoids and its structure-effect relationship. Arch Pharm Res. 1989;12:26\u201333.","journal-title":"Arch Pharm Res"},{"key":"3857_CR76","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2174\/138945006776359331","volume":"7","author":"D Delmas","year":"2006","unstructured":"Delmas D, Lancon A, Colin D, Jannin B, Latruffe N. Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer. Curr Drug Targets. 2006;7:423\u201342.","journal-title":"Curr Drug Targets"},{"key":"3857_CR77","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1021\/jf60204a061","volume":"24","author":"NP Sen","year":"1976","unstructured":"Sen NP, Donaldson B, Seaman S, Iyengar JR, Miles WF. Inhibition of nitrosamine formation in fried bacon by propyl gallate and L-ascorbyl palmitate. J Agric Food Chem. 1976;24:397\u2013401.","journal-title":"J Agric Food Chem"},{"key":"3857_CR78","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S0278-6915(00)00042-9","volume":"38","author":"AAM Botterweck","year":"2000","unstructured":"Botterweck AAM, Verhagen H, Goldbohm RA, Kleinjans J, van den Brandt PA. Intake of butylated hydroxyanisole and butylated hydroxytoluene and stomach cancer risk: results from analyses in the Netherlands Cohort Study. Food Chem Toxicol. 2000;38:599\u2013605.","journal-title":"Food Chem Toxicol"},{"key":"3857_CR79","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/jf980130f","volume":"46","author":"B Rousseau","year":"1998","unstructured":"Rousseau B, Rosazza JPN. Reaction of Ferulic Acid with Nitrite: Formation of 7-Hydroxy-6-methoxy-1,2(4 H )-benzoxazin-4-one. J Agric Food Chem. 1998;46:3314\u20137.","journal-title":"J Agric Food Chem"},{"key":"3857_CR80","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1021\/jo015965v","volume":"67","author":"A Napolitano","year":"2002","unstructured":"Napolitano A, d\u2019Ischia M. New Insights into the Acid-Promoted Reaction of Caffeic Acid and Its Esters with Nitrite: Decarboxylation Drives Chain Nitrosation Pathways toward Novel Oxime Derivatives and Oxidation\/Fragmentation Products Thereof. J Org Chem. 2002;67:803\u201310.","journal-title":"J Org Chem"},{"key":"3857_CR81","doi-asserted-by":"crossref","unstructured":"Aishwarya D, Nikhil P, M R, Natesan S, Ravichandiran V, Peraman R. Comparative Evaluation of Antioxidants as Potent Inhibitors of N-nitrosodimethylamine Formation in Metformin Hydrochloride Drug Products. 2024.","DOI":"10.2139\/ssrn.4927258"},{"key":"3857_CR82","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/0278-6915(92)90196-R","volume":"30","author":"T Kato","year":"1992","unstructured":"Kato T, Kikugawa K. Proteins and amino acids as scavengers of nitrite: inhibitory effect on the formation of nitrosodimethylamine and diazoquinone. Food Chem Toxicol. 1992;30:617\u201326.","journal-title":"Food Chem Toxicol"},{"key":"3857_CR83","doi-asserted-by":"publisher","first-page":"8625","DOI":"10.1021\/jo026154+","volume":"67","author":"L Grossi","year":"2002","unstructured":"Grossi L, Montevecchi PC. S-nitrosocysteine and cystine from reaction of cysteine with nitrous acid. A kinetic investigation1. J Org Chem. 2002;67:8625\u201330.","journal-title":"J Org Chem"},{"key":"3857_CR84","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0165-7992(92)90084-U","volume":"282","author":"Y Kako","year":"1992","unstructured":"Kako Y, Toyoda Y, Hatanaka Y, Suwa Y, Nukaya H, Nagao M. Inhibition of mutagenesis by p-aminobenzoic acid as a nitrite scavenger. Mutat Res Lett. 1992;282:119\u201325.","journal-title":"Mutat Res Lett"},{"key":"3857_CR85","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.freeradbiomed.2005.08.031","volume":"40","author":"SYH Lee","year":"2006","unstructured":"Lee SYH, Munerol B, Pollard S, Youdim KA, Pannala AS, Kuhnle GGC, et al. The reaction of flavanols with nitrous acid protects against N-nitrosamine formation and leads to the formation of nitroso derivatives which inhibit cancer cell growth. Free Radic Biol Med. 2006;40:323\u201334.","journal-title":"Free Radic Biol Med"},{"key":"3857_CR86","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1383-5718(97)00178-2","volume":"412","author":"K Tanaka","year":"1998","unstructured":"Tanaka K, Hayatsu T, Negishi T, Hayatsu H. Inhibition of N-nitrosation of secondary amines in vitro by tea extracts and catechins. Mutation Research\/Genetic Toxicology and Environmental Mutagenesis. 1998;412:91\u20138.","journal-title":"Mutation Research\/Genetic Toxicology and Environmental Mutagenesis"},{"key":"3857_CR87","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.tiv.2009.07.022","volume":"23","author":"ME Delgado","year":"2009","unstructured":"Delgado ME, Haza AI, Garc\u00eda A, Morales P. Myricetin, quercetin, (+)-catechin and (\u2212)-epicatechin protect against N-nitrosamines-induced DNA damage in human hepatoma cells. Toxicol In Vitro. 2009;23:1292\u20137.","journal-title":"Toxicol In Vitro"},{"key":"3857_CR88","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/10942912.2019.1578792","volume":"22","author":"L Li","year":"2019","unstructured":"Li L, Ji H. Protective effects of epicatechin on the oxidation and N-nitrosamine formation of oxidatively stressed myofibrillar protein. Int J Food Prop. 2019;22:186\u201397.","journal-title":"Int J Food Prop"},{"key":"3857_CR89","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1039\/D3FO02877A","volume":"15","author":"S Ren","year":"2024","unstructured":"Ren S, Hu H, Zhu X, Wang S, Zhao W, Xie D, et al. Inhibitory effects and reactions of gallic acid, catechin, and procyanidin B2 with nitrosation under stomach simulating conditions. Food Funct. 2024;15:3130\u201340.","journal-title":"Food Funct"},{"key":"3857_CR90","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1021\/tx2003118","volume":"24","author":"M d\u2019Ischia","year":"2011","unstructured":"d\u2019Ischia M, Napolitano A, Manini P, Panzella L. Secondary Targets of Nitrite-Derived Reactive Nitrogen Species: Nitrosation\/Nitration Pathways, Antioxidant Defense Mechanisms and Toxicological Implications. Chem Res Toxicol. 2011;24:2071\u201392.","journal-title":"Chem Res Toxicol"},{"key":"3857_CR91","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1021\/acs.oprd.2c00366","volume":"27","author":"IW Ashworth","year":"2023","unstructured":"Ashworth IW, Dey D, Dirat O, McDaid P, Lee D, Moser J, et al. Formation of Dialkyl- N -nitrosamines in Aqueous Solution: An Experimental Validation of a Conservative Predictive Model and a Comparison of the Rates of Dialkyl and Trialkylamine Nitrosation. Org Process Res Dev. 2023;27:1759\u201366.","journal-title":"Org Process Res Dev"},{"key":"3857_CR92","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0041-008X(75)90255-0","volume":"31","author":"SS Mirvish","year":"1975","unstructured":"Mirvish SS. Formation of N-nitroso compounds: Chemistry, kinetics, and in vivo occurrence. Toxicol Appl Pharmacol. 1975;31:325\u201351.","journal-title":"Toxicol Appl Pharmacol"},{"key":"3857_CR93","unstructured":"IPEC federation. The role of excipients in determining N-nitrosamine risks for drug products. 2022. Available from: https:\/\/ipec-federation.org\/wp-content\/uploads\/2022\/02\/202203_IF_Nitrosamines-Position-Paper_FINAL.pdf. Accessed 21 Nov 2024."},{"key":"3857_CR94","doi-asserted-by":"publisher","first-page":"121740","DOI":"10.1016\/j.ijpharm.2022.121740","volume":"620","author":"J Schlingemann","year":"2022","unstructured":"Schlingemann J, Boucley C, Hickert S, Bourasseau L, Walker M, Celdran C, et al. Avoiding N-nitrosodimethylamine formation in metformin pharmaceuticals by limiting dimethylamine and nitrite. Int J Pharm. 2022;620:121740.","journal-title":"Int J Pharm"},{"key":"3857_CR95","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.xphs.2023.02.014","volume":"112","author":"L-E Carloni","year":"2023","unstructured":"Carloni L-E, Lochner S, Sterckx H, Van Daele T. Solid State Kinetics of Nitrosation Using Native Sources of Nitrite. J Pharm Sci. 2023;112:1324\u201332.","journal-title":"J Pharm Sci"},{"key":"3857_CR96","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1515\/amm-2016-0309","volume":"61","author":"A Poskart","year":"2016","unstructured":"Poskart A, Radomiak H, Niegodajew P, Zajemska M, Musia\u0142 D. The analysis of nitrogen oxides formation during oxygen-enriched combustion of natural gas. Arch Metall Mater. 2016;61:1925\u201330.","journal-title":"Arch Metall Mater"},{"key":"3857_CR97","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/j.2050-0416.1986.tb04373.x","volume":"92","author":"T Wainright","year":"1986","unstructured":"Wainright T. THE CHEMISTRY OF NITROSAMINE FORMATION: RELEVANCE TO MALTING AND BREWING. J Inst Brew. 1986;92:49\u201364.","journal-title":"J Inst Brew"},{"key":"3857_CR98","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1021\/acs.oprd.3c00118","volume":"27","author":"NS Murphy","year":"2023","unstructured":"Murphy NS, O\u2019Connor DC, Gavins GC, James L, Lockett JP, McManus JA, et al. Identifying the Risk of Formation of Nitrosamines and Other Potentially Mutagenic Impurities during API Manufacture Using In Silico Risk Assessment. Org Process Res Dev. 2023;27:1812\u20139.","journal-title":"Org Process Res Dev"},{"key":"3857_CR99","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/ani9100754","volume":"9","author":"RC Hubrecht","year":"2019","unstructured":"Hubrecht RC, Carter E. The 3Rs and humane experimental technique: implementing change. Animals. 2019;9:754.","journal-title":"Animals"},{"key":"3857_CR100","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.mrgentox.2018.05.021","volume":"832","author":"F Marchetti","year":"2018","unstructured":"Marchetti F, Aardema MJ, Beevers C, van Benthem J, Godschalk R, Williams A, et al. Identifying germ cell mutagens using OECD test guideline 488 (transgenic rodent somatic and germ cell gene mutation assays) and integration with somatic cell testing. Mutation Research\/Genetic Toxicology and Environmental Mutagenesis. 2018;832:7\u201318.","journal-title":"Mutation Research\/Genetic Toxicology and Environmental Mutagenesis"},{"key":"3857_CR101","doi-asserted-by":"publisher","first-page":"105247","DOI":"10.1016\/j.yrtph.2022.105247","volume":"135","author":"A Trejo-Martin","year":"2022","unstructured":"Trejo-Martin A, Bercu JP, Thresher A, Tennant RE, Thomas RF, Cross K, et al. Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines. Regul Toxicol Pharmacol. 2022;135:105247.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3857_CR102","unstructured":"ICH Q3A (R2). IMPURITIES IN NEW DRUG SUBSTANCES Q3A(R2). 2006 Oct."},{"key":"3857_CR103","doi-asserted-by":"crossref","unstructured":"Schmezer P, Eckert C, Liegibel UM, Klein RG, Bartsch H. Use of transgenic mutational test systems in risk assessment of carcinogens. Diversification in Toxicology\u2014Man and Environment: Proceedings of the 1997 EUROTOX Congress Meeting Held in \u00c5rhus, Denmark, June 25\u201328, 1997. Springer; 1998. p. 321\u201330.","DOI":"10.1007\/978-3-642-46856-8_29"},{"key":"3857_CR104","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/01926230490424761","volume":"32","author":"D Jacobson-Kram","year":"2004","unstructured":"Jacobson-Kram D, Sistare FD, Jacobs AC. Use of transgenic mice in carcinogenicity hazard assessment. Toxicol Pathol. 2004;32:49\u201352.","journal-title":"Toxicol Pathol"},{"key":"3857_CR105","doi-asserted-by":"crossref","unstructured":"Seo J-E, Le Y, Revollo J, Miranda-Colon J, Xu H, McKinzie P, et al. Evaluating the mutagenicity of N-nitrosodimethylamine in 2D and 3D HepaRG cell cultures using error-corrected next generation sequencing. Arch Toxicol. 2024;1\u201317.","DOI":"10.1007\/s00204-024-03731-4"},{"key":"3857_CR106","doi-asserted-by":"publisher","first-page":"108466","DOI":"10.1016\/j.mrrev.2023.108466","volume":"792","author":"F Marchetti","year":"2023","unstructured":"Marchetti F, Cardoso R, Chen CL, Douglas GR, Elloway J, Escobar PA, et al. Error-corrected next generation sequencing\u2013promises and challenges for genotoxicity and cancer risk assessment. Mutation Research\/Reviews in Mutation Research. 2023;792:108466.","journal-title":"Mutation Research\/Reviews in Mutation Research"},{"key":"3857_CR107","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/d41573-023-00014-y","volume":"22","author":"F Marchetti","year":"2023","unstructured":"Marchetti F, Cardoso R, Chen CL, Douglas GR, Elloway J, Escobar PA, et al. Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing. Nat Rev Drug Discov. 2023;22:165\u20136.","journal-title":"Nat Rev Drug Discov"},{"key":"3857_CR108","doi-asserted-by":"publisher","first-page":"101661","DOI":"10.1016\/j.biologicals.2022.11.003","volume":"81","author":"PW Barone","year":"2023","unstructured":"Barone PW, Keumurian FJ, Neufeld C, Koenigsberg A, Kiss R, Leung J, et al. Historical evaluation of the in vivo adventitious virus test and its potential for replacement with next generation sequencing (NGS). Biologicals. 2023;81:101661.","journal-title":"Biologicals"},{"key":"3857_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrgentox.2016.03.008","volume":"802","author":"T Morita","year":"2016","unstructured":"Morita T, Hamada S, Masumura K, Wakata A, Maniwa J, Takasawa H, et al. Evaluation of the sensitivity and specificity of in vivo erythrocyte micronucleus and transgenic rodent gene mutation tests to detect rodent carcinogens. Mutation Research\/Genetic Toxicology and Environmental Mutagenesis. 2016;802:1\u201329.","journal-title":"Mutation Research\/Genetic Toxicology and Environmental Mutagenesis"},{"key":"3857_CR110","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/em.22615","volume":"65","author":"S Zhang","year":"2024","unstructured":"Zhang S, Coffing SL, Gunther WC, Homiski ML, Spellman RA, Van P, et al. Assessing the genotoxicity of N-nitrosodiethylamine with three in vivo endpoints in male Big Blue\u00ae transgenic and wild-type C 57 BL\/6 N mice. Environ Mol Mutagen. 2024;65:190\u2013202.","journal-title":"Environ Mol Mutagen"},{"key":"3857_CR111","unstructured":"ICH M7(R2). ASSESSMENT AND CONTROL OF DNA REACTIVE (MUTAGENIC) IMPURITIES IN PHARMACEUTICALS TO LIMIT POTENTIAL CARCINOGENICRISK M7(R2). 2023 Apr."},{"key":"3857_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mrrev.2005.04.002","volume":"590","author":"IB Lambert","year":"2005","unstructured":"Lambert IB, Singer TM, Boucher SE, Douglas GR. Detailed review of transgenic rodent mutation assays. Mutation Research\/Reviews in Mutation Research. 2005;590:1\u2013280.","journal-title":"Mutation Research\/Reviews in Mutation Research"},{"key":"3857_CR113","unstructured":"OECD. Detailed Review Paper on Transgenic Rodent Mutation Assays. OECD; 2009."},{"key":"3857_CR114","unstructured":"Dr George Johnson. Review of nitrosamine drug substance related impurities (NDSRIs) in pharmaceutical drugs: risk assessments, acceptable intakes, and QSAR tools. 2023. Available from: https:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2023\/10\/Review-of-Nitrosamine-drug-substance-related-impurities-in-Pharma-report.pdf. Accessed 3 Oct 2024."},{"key":"3857_CR115","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/0027-5107(94)90261-5","volume":"307","author":"H Tinwell","year":"1994","unstructured":"Tinwell H, Lefevre PA, Ashby J. Mutation studies with dimethyl nitrosamine in young and old lac I transgenic mice. Mutation Research\/Fundamental and Molecular Mechanisms of Mutagenesis. 1994;307:501\u20138.","journal-title":"Mutation Research\/Fundamental and Molecular Mechanisms of Mutagenesis"},{"key":"3857_CR116","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jmoldx.2013.09.003","volume":"16","author":"DH Spencer","year":"2014","unstructured":"Spencer DH, Tyagi M, Vallania F, Bredemeyer AJ, Pfeifer JD, Mitra RD, et al. Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data. J Mol Diagn. 2014;16:75\u201388.","journal-title":"J Mol Diagn"},{"key":"3857_CR117","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrg.2017.117","volume":"19","author":"JJ Salk","year":"2018","unstructured":"Salk JJ, Schmitt MW, Loeb LA. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet. 2018;19:269\u201385.","journal-title":"Nat Rev Genet"},{"key":"3857_CR118","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/em.22342","volume":"61","author":"JJ Salk","year":"2020","unstructured":"Salk JJ, Kennedy SR. Next-generation genotoxicology: using modern sequencing technologies to assess somatic mutagenesis and cancer risk. Environ Mol Mutagen. 2020;61:135\u201351.","journal-title":"Environ Mol Mutagen"},{"key":"3857_CR119","doi-asserted-by":"publisher","first-page":"103200","DOI":"10.1016\/j.dnarep.2021.103200","volume":"107","author":"A Abbasi","year":"2021","unstructured":"Abbasi A, Alexandrov LB. Significance and limitations of the use of next-generation sequencing technologies for detecting mutational signatures. DNA Repair (Amst). 2021;107:103200.","journal-title":"DNA Repair (Amst)"},{"key":"3857_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s42764-021-00058-7","volume":"3","author":"Y Luan","year":"2022","unstructured":"Luan Y, Honma M. Genotoxicity testing and recent advances. Genome Instab Dis. 2022;3:1\u201321.","journal-title":"Genome Instab Dis"},{"key":"3857_CR121","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.humimm.2021.02.012","volume":"82","author":"T Hu","year":"2021","unstructured":"Hu T, Chitnis N, Monos D, Dinh A. Next-generation sequencing technologies: An overview. Hum Immunol. 2021;82:801\u201311.","journal-title":"Hum Immunol"},{"key":"3857_CR122","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/bfgp\/elr033","volume":"10","author":"F Mertes","year":"2011","unstructured":"Mertes F, ElSharawy A, Sauer S, van Helvoort JMLM, Van Der Zaag PJ, Franke A, et al. Targeted enrichment of genomic DNA regions for next-generation sequencing. Brief Funct Genomics. 2011;10:374\u201386.","journal-title":"Brief Funct Genomics"},{"key":"3857_CR123","doi-asserted-by":"publisher","first-page":"e64271","DOI":"10.1371\/journal.pone.0064271","volume":"8","author":"S-W Han","year":"2013","unstructured":"Han S-W, Kim H-P, Shin J-Y, Jeong E-G, Lee W-C, Lee K-H, et al. Targeted sequencing of cancer-related genes in colorectal cancer using next-generation sequencing. PLoS ONE. 2013;8:e64271.","journal-title":"PLoS ONE"},{"key":"3857_CR124","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/gcc.22923","volume":"60","author":"I Vanden Bempt","year":"2021","unstructured":"Vanden Bempt I, Vander Borght S, Sciot R, Spans L, Claerhout S, Brems H, et al. Comprehensive targeted next-generation sequencing approach in the molecular diagnosis of gastrointestinal stromal tumor. Genes Chromosomes Cancer. 2021;60:239\u201349.","journal-title":"Genes Chromosomes Cancer"},{"key":"3857_CR125","doi-asserted-by":"publisher","first-page":"7354","DOI":"10.1039\/D0CS00647E","volume":"49","author":"C Mingard","year":"2020","unstructured":"Mingard C, Wu J, McKeague M, Sturla SJ. Next-generation DNA damage sequencing. Chem Soc Rev. 2020;49:7354\u201377.","journal-title":"Chem Soc Rev"},{"key":"3857_CR126","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/10590501.2017.1328831","volume":"35","author":"H Du","year":"2017","unstructured":"Du H, Pan B, Chen T. Evaluation of chemical mutagenicity using next generation sequencing: A review. J Environ Sci Health C. 2017;35:140\u201358.","journal-title":"J Environ Sci Health C"},{"key":"3857_CR127","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/em.22045","volume":"58","author":"KL Dearfield","year":"2017","unstructured":"Dearfield KL, Gollapudi BB, Bemis JC, Benz RD, Douglas GR, Elespuru RK, et al. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations. Environ Mol Mutagen. 2017;58:264\u201383.","journal-title":"Environ Mol Mutagen"},{"key":"3857_CR128","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cotox.2019.02.010","volume":"18","author":"BA Merrick","year":"2019","unstructured":"Merrick BA. Next-generation sequencing data for use in risk assessment. Curr Opin Toxicol. 2019;18:18\u201326.","journal-title":"Curr Opin Toxicol"},{"key":"3857_CR129","doi-asserted-by":"crossref","unstructured":"Menon V, Brash DE. Next-Generation Sequencing Methodologies to Detect Low-Frequency Mutations:\u201cCatch Me If You Can.\u201d Mutation Research\/Reviews in Mutation Research. 2023;108471.","DOI":"10.1016\/j.mrrev.2023.108471"},{"key":"3857_CR130","first-page":"77","volume":"173","author":"PB McKinzie","year":"2020","unstructured":"McKinzie PB, Bishop ME. A Streamlined and high-throughput error-corrected next-generation sequencing method for low variant allele frequency quantitation. Toxicol Sci. 2020;173:77\u201385.","journal-title":"Toxicol Sci"},{"key":"3857_CR131","doi-asserted-by":"publisher","first-page":"503685","DOI":"10.1016\/j.mrgentox.2023.503685","volume":"891","author":"JP Bercu","year":"2023","unstructured":"Bercu JP, Zhang S, Sobol Z, Escobar PA, Van P, Schuler M. Comparison of the transgenic rodent mutation assay, error corrected next generation duplex sequencing, and the alkaline comet assay to detect dose-related mutations following exposure to N-nitrosodiethylamine. Mutation Research\/Genetic Toxicology and Environmental Mutagenesis. 2023;891:503685.","journal-title":"Mutation Research\/Genetic Toxicology and Environmental Mutagenesis"},{"key":"3857_CR132","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/0015-6264(71)90306-3","volume":"9","author":"PN Magee","year":"1971","unstructured":"Magee PN. Toxicity of nitrosamines: Their possible human health hazards. Food Cosmet Toxicol. 1971;9:207\u201318.","journal-title":"Food Cosmet Toxicol"},{"key":"3857_CR133","doi-asserted-by":"publisher","first-page":"105403","DOI":"10.1016\/j.yrtph.2023.105403","volume":"141","author":"DJ Snodin","year":"2023","unstructured":"Snodin DJ. Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines. Regul Toxicol Pharmacol. 2023;141:105403.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3857_CR134","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/0891-5849(89)90144-5","volume":"7","author":"H Bartsch","year":"1989","unstructured":"Bartsch H, Hietanen E, Malaveille C. Carcinogenic nitrosamines: free radical aspects of their action. Free Radic Biol Med. 1989;7:637\u201344.","journal-title":"Free Radic Biol Med"},{"key":"3857_CR135","doi-asserted-by":"publisher","first-page":"105681","DOI":"10.1016\/j.yrtph.2024.105681","volume":"152","author":"MW Powley","year":"2024","unstructured":"Powley MW, Sobol Z, Johnson GE, Clark RW, Dalby SM, Ykoruk BA, et al. N-nitrosamine impurity risk assessment in pharmaceuticals: Utilizing In vivo mutation relative potency comparison to establish an acceptable intake for NTTP. Regul Toxicol Pharmacol. 2024;152:105681.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3857_CR136","doi-asserted-by":"publisher","first-page":"11144","DOI":"10.1074\/jbc.RA119.009054","volume":"294","author":"H Du","year":"2019","unstructured":"Du H, Wang P, Li L, Wang Y. Repair and translesion synthesis of O6-alkylguanine DNA lesions in human cells. J Biol Chem. 2019;294:11144\u201353.","journal-title":"J Biol Chem"},{"key":"3857_CR137","doi-asserted-by":"crossref","unstructured":"MacGregor JT, Fr\u00f6tschl R, White PA, Crump KS, Eastmond DA, Fukushima S, et al. IWGT report on quantitative approaches to genotoxicity risk assessment I. Methods and metrics for defining exposure\u2013response relationships and points of departure (PoDs). Mutation Research\/Genetic Toxicology and Environmental Mutagenesis. 2015;783:55\u201365.","DOI":"10.1016\/j.mrgentox.2014.09.011"},{"key":"3857_CR138","doi-asserted-by":"crossref","unstructured":"MacGregor JT, Fr\u00f6tschl R, White PA, Crump KS, Eastmond DA, Fukushima S, et al. IWGT report on quantitative approaches to genotoxicity risk assessment II. Use of point-of-departure (PoD) metrics in defining acceptable exposure limits and assessing human risk. Mutation Research\/Genetic Toxicology and Environmental Mutagenesis. 2015;783:66\u201378.","DOI":"10.1016\/j.mrgentox.2014.10.008"},{"key":"3857_CR139","doi-asserted-by":"publisher","first-page":"104749","DOI":"10.1016\/j.yrtph.2020.104749","volume":"116","author":"A Thresher","year":"2020","unstructured":"Thresher A, Foster R, Ponting DJ, Stalford SA, Tennant RE, Thomas R. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data. Regul Toxicol Pharmacol. 2020;116:104749.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3857_CR140","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/em.22446","volume":"62","author":"GE Johnson","year":"2021","unstructured":"Johnson GE, Dobo K, Gollapudi B, Harvey J, Kenny J, Kenyon M, et al. Permitted daily exposure limits for noteworthy N-nitrosamines. Environ Mol Mutagen. 2021;62:293\u2013305.","journal-title":"Environ Mol Mutagen"},{"key":"3857_CR141","doi-asserted-by":"crossref","unstructured":"Gandhi RD, Hickert S, Hoevelmann Y, Mee CD, Schlingemann J, Adams A, et al. Escaping the cohort of concern: in vitro experimental evidence supports non-mutagenicity of N-nitroso-hydrochlorothiazide. Arch Toxicol. 2024;1\u201314.","DOI":"10.1007\/s00204-024-03859-3"},{"key":"3857_CR142","doi-asserted-by":"publisher","first-page":"105245","DOI":"10.1016\/j.yrtph.2022.105245","volume":"134","author":"S Glowienke","year":"2022","unstructured":"Glowienke S, Onken U, Elhajouji A, Muthusamy S, Sangana R, Martus H-J, et al. Genotoxicity evaluation of a valsartan-related complex N-nitroso-impurity. Regul Toxicol Pharmacol. 2022;134:105245.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3857_CR143","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41021-016-0064-6","volume":"39","author":"Y Aoki","year":"2017","unstructured":"Aoki Y. Evaluation of in vivo mutagenesis for assessing the health risk of air pollutants. Genes and Environment. 2017;39:16.","journal-title":"Genes and Environment"},{"key":"3857_CR144","doi-asserted-by":"publisher","first-page":"15584","DOI":"10.1021\/acs.jmedchem.2c01498","volume":"65","author":"DJ Ponting","year":"2022","unstructured":"Ponting DJ, Dobo KL, Kenyon MO, Kalgutkar AS. Strategies for assessing acceptable intakes for novel N-nitrosamines derived from active pharmaceutical ingredients. J Med Chem. 2022;65:15584\u2013607.","journal-title":"J Med Chem"},{"key":"3857_CR145","doi-asserted-by":"publisher","first-page":"100186","DOI":"10.1016\/j.comtox.2021.100186","volume":"20","author":"KP Cross","year":"2021","unstructured":"Cross KP, Ponting DJ. Developing structure-activity relationships for N-nitrosamine activity. Comput Toxicol. 2021;20:100186.","journal-title":"Computational toxicology"},{"key":"3857_CR146","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1021\/acs.chemrestox.2c00199","volume":"35","author":"R Thomas","year":"2022","unstructured":"Thomas R, Tennant RE, Oliveira AAF, Ponting DJ. What makes a potent nitrosamine? Statistical validation of expert-derived structure\u2013activity relationships. Chem Res Toxicol. 2022;35:1997\u20132013.","journal-title":"Chem Res Toxicol"},{"key":"3857_CR147","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1021\/acs.chemrestox.1c00369","volume":"35","author":"KL Dobo","year":"2022","unstructured":"Dobo KL, Kenyon MO, Dirat O, Engel M, Fleetwood A, Martin M, et al. Practical and science-based strategy for establishing acceptable intakes for drug product N-nitrosamine impurities. Chem Res Toxicol. 2022;35:475\u201389.","journal-title":"Chem Res Toxicol"},{"key":"3857_CR148","unstructured":"EFPIA. Workflows for quality risk management of nitrosamine risks in medicines. 2022. Available from: https:\/\/www.efpia.eu\/media\/676632\/efpia-nitrosamines-quality-risk-management-workflows-sep-2022.pdf. Accessed 19 Nov 2024."},{"key":"3857_CR149","first-page":"1","volume":"58","author":"R Peto","year":"1984","unstructured":"Peto R, Pike MC, Bernstein L, Gold LS, Ames BN. The TD50: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic-exposure animal experiments. Environ Health Perspect. 1984;58:1\u20138.","journal-title":"Environ Health Perspect"},{"key":"3857_CR150","unstructured":"Akhila JS, Shyamjith D, Alwar MC. Acute toxicity studies and determination of median lethal dose. Curr Sci. 2007;917\u201320."},{"key":"3857_CR151","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.fct.2006.07.004","volume":"44","author":"J O\u2019Brien","year":"2006","unstructured":"O\u2019Brien J, Renwick AG, Constable A, Dybing E, M\u00fcller DJG, Schlatter J, et al. Approaches to the risk assessment of genotoxic carcinogens in food: a critical appraisal. Food Chem Toxicol. 2006;44:1613\u201335.","journal-title":"Food Chem Toxicol"},{"key":"3857_CR152","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1039\/c9tx00118b","volume":"8","author":"A Thresher","year":"2019","unstructured":"Thresher A, Gosling JP, Williams R. Generation of TD50 values for carcinogenicity study data. Toxicol Res (Camb). 2019;8:696\u2013703.","journal-title":"Toxicol Res (Camb)"},{"key":"3857_CR153","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/10408440902810329","volume":"39","author":"H-G Neumann","year":"2009","unstructured":"Neumann H-G. Risk assessment of chemical carcinogens and thresholds. Crit Rev Toxicol. 2009;39:449\u201361.","journal-title":"Crit Rev Toxicol"},{"key":"3857_CR154","doi-asserted-by":"crossref","unstructured":"Sawyer C, Peto R, Bernstein L, Pike MC. Calculation of carcinogenic potency from long-term animal carcinogenesis experiments. Biometrics. 1984;27\u201340.","DOI":"10.2307\/2530741"},{"key":"3857_CR155","doi-asserted-by":"crossref","unstructured":"Hartung T, Hoffmann S. Food for thought... on in silico methods in toxicology. ALTEX-Alternatives to animal experimentation. 2009;26:155\u201366.","DOI":"10.14573\/altex.2009.3.155"},{"key":"3857_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00204-019-02613-4","volume":"94","author":"D Krewski","year":"2020","unstructured":"Krewski D, Andersen ME, Tyshenko MG, Krishnan K, Hartung T, Boekelheide K, et al. Toxicity testing in the 21st century: progress in the past decade and future perspectives. Arch Toxicol. 2020;94:1\u201358.","journal-title":"Arch Toxicol"},{"key":"3857_CR157","unstructured":"CPDB. The carcinogenic potency database (CPDB). Available from: https:\/\/files.toxplanet.com\/cpdb\/index.html. Accessed 19 Nov 2024."},{"key":"3857_CR158","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0272-0590(86)90239-3","volume":"6","author":"LS Gold","year":"1986","unstructured":"Gold LS, Bernstein L, Kaldor J, Backman G, Hoel D. An empirical comparison of methods used to estimate carcinogenic potency in long-term animal bioassays: lifetable vs summary incidence data. Fundam Appl Toxicol. 1986;6:263\u20139.","journal-title":"Fundam Appl Toxicol"},{"key":"3857_CR159","doi-asserted-by":"publisher","first-page":"110864","DOI":"10.1016\/j.cbi.2024.110864","volume":"389","author":"A Frydrych","year":"2024","unstructured":"Frydrych A, Jurowski K. The comprehensive prediction of carcinogenic potency and tumorigenic dose (TD50) for two problematic N-nitrosamines in food: NMAMPA and NMAMBA using toxicology in silico methods. Chem Biol Interact. 2024;389:110864.","journal-title":"Chem Biol Interact"},{"key":"3857_CR160","doi-asserted-by":"publisher","first-page":"105415","DOI":"10.1016\/j.yrtph.2023.105415","volume":"142","author":"JP Bercu","year":"2023","unstructured":"Bercu JP, Masuda-Herrera M, Trejo-Martin A, Sura P, Jolly R, Kenyon M, et al. Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs). Regul Toxicol Pharmacol. 2023;142:105415.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3857_CR161","doi-asserted-by":"publisher","first-page":"105640","DOI":"10.1016\/j.yrtph.2024.105640","volume":"150","author":"NL Kruhlak","year":"2024","unstructured":"Kruhlak NL, Schmidt M, Froetschl R, Graber S, Haas B, Horne I, et al. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA). Regul Toxicol Pharmacol. 2024;150:105640.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3857_CR162","unstructured":"EMA. Questions and answers for marketing authorisation holders\/applicants on the CHMP opinion for the article 5(3) of regulation (EC) No 726\/2004 referral on nitrosamine impurities in human medicinal products enhanced ames test conditions for N-nitrosamines. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/appendix-3-enhanced-ames-test-conditions-n-nitrosamines_en.pdf. Accessed 24 Oct 2024."},{"key":"3857_CR163","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1016\/j.xphs.2023.10.001","volume":"112","author":"MJ Burns","year":"2023","unstructured":"Burns MJ, Ponting DJ, Foster RS, Thornton BP, Romero NE, Smith GF, et al. Revisiting the landscape of potential small and drug substance related nitrosamines in pharmaceuticals. J Pharm Sci. 2023;112:3005\u201311.","journal-title":"J Pharm Sci"},{"key":"3857_CR164","unstructured":"Oliveira AA; M-AC; PDJ; TRE; WA-L. Collaborative analysis of complex nitrosamines. Presented at the 2022 Society of Toxicology Annual Meeting; Abstract 5063. 2022"},{"key":"3857_CR165","doi-asserted-by":"publisher","first-page":"105505","DOI":"10.1016\/j.yrtph.2023.105505","volume":"145","author":"J Fine","year":"2023","unstructured":"Fine J, Allain L, Schlingemann J, Ponting DJ, Thomas R, Johnson GE. Nitrosamine acceptable intakes should consider variation in molecular weight: The implication of stoichiometric DNA damage. Regul Toxicol Pharmacol. 2023;145:105505.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3857_CR166","first-page":"187","volume":"27","author":"AM Lynch","year":"2023","unstructured":"Lynch AM. Defining a NOGEL for mutation induction in Muta\u2122 Mouse following exposure to N-Nitrosodimethylamine (NDMA). Spanish Journal of Environmental Mutagenesis and Genomics. 2023;27:187.","journal-title":"Spanish Journal of Environmental Mutagenesis and Genomics"},{"key":"3857_CR167","doi-asserted-by":"publisher","first-page":"105672","DOI":"10.1016\/j.yrtph.2024.105672","volume":"152","author":"RA Jolly","year":"2024","unstructured":"Jolly RA, Cornwell PD, Noteboom J, Sayyed FB, Thapa B, Buckley LA. Estimation of acceptable daily intake values based on modeling and in vivo mutagenicity of NDSRIs of fluoxetine, duloxetine and atomoxetine. Regul Toxicol Pharmacol. 2024;152:105672.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3857_CR168","doi-asserted-by":"publisher","first-page":"105730","DOI":"10.1016\/j.yrtph.2024.105730","volume":"154","author":"X Li","year":"2024","unstructured":"Li X, Le Y, Guo X, King ST, Dorsam RT, Atrakchi AH, et al. Mutagenicity and genotoxicity evaluation of 15 nitrosamine drug substance-related impurities in human TK6 cells. Regul Toxicol Pharmacol. 2024;154:105730.","journal-title":"Regul Toxicol Pharmacol"},{"key":"3857_CR169","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/em.22618","volume":"65","author":"J Cheung","year":"2024","unstructured":"Cheung J, Dobo K, Zhang S, Nudelman R, Schmidt F, Wenzel J, et al. Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potential. Environ Mol Mutagen. 2024;65:203\u201321.","journal-title":"Environ Mol Mutagen"},{"key":"3857_CR170","doi-asserted-by":"publisher","first-page":"105410","DOI":"10.1016\/j.yrtph.2023.105410","volume":"141","author":"X Li","year":"2023","unstructured":"Li X, Le Y, Seo J-E, Guo X, Li Y, Chen S, et al. Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays. Regul Toxicol Pharmacol. 2023;141:105410.","journal-title":"Regul Toxicol Pharmacol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03857-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-025-03857-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-025-03857-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T14:03:23Z","timestamp":1746540203000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-025-03857-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":170,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3857"],"URL":"https:\/\/doi.org\/10.1007\/s11095-025-03857-9","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"20 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest with respect to the authorship and\/or, publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}